In Vitro: SJF620 is a PROTAC that retains potent degradation of BTK in cellular assays with a DC50 of 7.9 nM in Burkitt lymphoma cell line NAMALWA.
In Vivo: SJF620 has a super pharmacokinetic profile in mice (1 mg/kg; i.v.) with the half life (t1/2) of 1.64 h. SJF620 exhibits a significantly better pharmacokinetic profile than MT802.